CGEN Quote, Trading Chart, Compugen Ltd.
home / stock / cgen / cgen quote
$9.33 Last:
4.13% Change Percent:
$9.01 Open:
$9.33 Previous Close:
$9.43 High:
$8.5 Low:
3,244,460 Volume:
02/26/2021 04:55:25 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-26 | 9.01 | 9.33 | 9.43 | 8.5 | 3,244,460 |
| 2021-02-25 | 10.83 | 8.96 | 10.99 | 8.83 | 4,187,526 |
| 2021-02-24 | 10.51 | 10.36 | 10.57 | 9.96 | 2,339,775 |
| 2021-02-23 | 11.68 | 10.51 | 11.7 | 10 | 3,043,428 |
| 2021-02-22 | 13.33 | 11.82 | 13.34 | 11.48 | 1,922,324 |
| 2021-02-19 | 12.74 | 12.77 | 13.325 | 12.735 | 894,237 |
| 2021-02-18 | 12.84 | 12.56 | 12.99 | 12 | 1,095,866 |
| 2021-02-17 | 13.02 | 13.21 | 13.49 | 12.745 | 911,649 |
| 2021-02-16 | 13.42 | 13.08 | 13.86 | 13.035 | 1,180,716 |
| 2021-02-15 | 12.87 | 13.13 | 13.23 | 12.73 | 643,856 |
| 2021-02-12 | 12.87 | 13.13 | 13.23 | 12.73 | 643,747 |
| 2021-02-11 | 13.18 | 13.01 | 13.3872 | 12.66 | 706,280 |
| 2021-02-10 | 13.91 | 13.13 | 14.08 | 12.87 | 778,177 |
| 2021-02-09 | 13.89 | 13.47 | 14.17 | 13.46 | 1,072,943 |
| 2021-02-08 | 13.37 | 13.77 | 14 | 13.34 | 1,300,464 |
| 2021-02-05 | 12.8 | 12.97 | 13.11 | 12.52 | 766,353 |
| 2021-02-04 | 12.93 | 12.53 | 13.3 | 12.48 | 959,817 |
| 2021-02-03 | 13.67 | 12.88 | 13.7362 | 12.87 | 791,342 |
| 2021-02-02 | 13.15 | 13.49 | 13.88 | 13.15 | 1,305,907 |
| 2021-02-01 | 12.47 | 13.04 | 13.18 | 12.39 | 1,142,830 |
Compugen Ltd. Company Name:
CGEN Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q4 2020 Earnings Call Feb 26, 2021 , 8:30 p.m. ET Operator Continue reading For further details see: Compugen Ltd. (CGEN) Q4 2020 Earnings Call Transcript
-
Compugen Reports Fourth Quarter and Full Year 2020 Results Encouraging signals of anti-tumor activity demonstrated across COM701 Phase 1 combination and monotherapy studies with durable responses, including a complete response, in tumor types typically unresponsive to checkpoint...
-
Compugen Announces Data Update from COM701 Phase 1 Clinical Trial Durable responses observed with COM701 in combination with Opdivo® including a confirmed complete response in a patient with prior progression on Opdivo® COM701 monotherapy demonstrates signals of an...